BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28806263)

  • 1. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
    Turkbey B; Mena E; Lindenberg L; Adler S; Bednarova S; Berman R; Ton AT; McKinney Y; Eclarinal P; Hill C; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Jacobs PM; Wood BJ; Pinto PA; Pomper MG; Choyke PL
    Clin Nucl Med; 2017 Oct; 42(10):735-740. PubMed ID: 28806263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
    Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of PSMA-based
    Mena E; Lindenberg ML; Shih JH; Adler S; Harmon S; Bergvall E; Citrin D; Dahut W; Ton AT; McKinney Y; Weaver J; Eclarinal P; Forest A; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Pinto P; Wood BJ; Jacobs P; Pomper MG; Choyke PL; Turkbey B
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):4-11. PubMed ID: 28894899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Comparison of
    Harmon SA; Bergvall E; Mena E; Shih JH; Adler S; McKinney Y; Mehralivand S; Citrin DE; Couvillon A; Madan RA; Gulley JL; Mease RC; Jacobs PM; Pomper MG; Turkbey B; Choyke PL; Lindenberg ML
    J Nucl Med; 2018 Nov; 59(11):1665-1671. PubMed ID: 29602821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Evaluation of
    Gaur S; Mena E; Harmon SA; Lindenberg ML; Adler S; Ton AT; Shih JH; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Mease RC; Pomper MG; Choyke PL; Turkbey B
    AJR Am J Roentgenol; 2020 Sep; 215(3):652-659. PubMed ID: 32755168
    [No Abstract]   [Full Text] [Related]  

  • 7. Findings in 1,123 Men with Preoperative
    Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
    J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [
    Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
    Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.
    Rowe SP; Macura KJ; Ciarallo A; Mena E; Blackford A; Nadal R; Antonarakis ES; Eisenberger MA; Carducci MA; Ross AE; Kantoff PW; Holt DP; Dannals RF; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2016 Jan; 57(1):46-53. PubMed ID: 26493203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    Reynolds HM; Williams S; Jackson P; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Haworth A
    BJU Int; 2019 Jun; 123(6):1020-1030. PubMed ID: 30536698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
    Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved specificity with
    Donato P; Roberts MJ; Morton A; Kyle S; Coughlin G; Esler R; Dunglison N; Gardiner RA; Yaxley J
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):20-30. PubMed ID: 30229528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of the diagnostic utility of
    Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective analysis of clinically significant prostate cancer detection with [
    Bodar YJL; Zwezerijnen BGJC; van der Voorn PJ; Jansen BHE; Smit RS; Kol SQ; Meijer D; de Bie K; Yaqub M; Windhorst BAD; Hendrikse HNH; Vis AN; Oprea-Lager DE
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1731-1742. PubMed ID: 34725727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
    BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
    Cho SY; Gage KL; Mease RC; Senthamizhchelvan S; Holt DP; Jeffrey-Kwanisai A; Endres CJ; Dannals RF; Sgouros G; Lodge M; Eisenberger MA; Rodriguez R; Carducci MA; Rojas C; Slusher BS; Kozikowski AP; Pomper MG
    J Nucl Med; 2012 Dec; 53(12):1883-91. PubMed ID: 23203246
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.